Back to top

Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 9.7%
July 14, 2017

Read MoreHide Full Article

Gemphire Therapeutics Inc. (GEMP - Free Report) was a big mover last session, as its shares rose over 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 45% in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Gemphire Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%

A better-ranked stock in the Medical - Biomedical and Genetics space is Enzo Biochem, Inc. (ENZ - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

More Stock News: This Is Bigger than the iPhone!                   

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Enzo Biochem, Inc. (ENZ) - free report >>

Gemphire Therapeutics Inc. (GEMP) - free report >>


More from Zacks Tale of the Tape

You May Like